The Efficacy of Baricitinib as a Treatment Option for Alopecia in Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes
May 2024
TLDR Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
Baricitinib, a Janus Kinase inhibitor, has demonstrated significant efficacy in promoting hair regrowth in patients with severe alopecia, as evidenced by improved Severity of Alopecia Tool (SALT) scores in the BRAVE-AA1 and BRAVE-AA2 trials. Patients treated with Baricitinib showed a marked improvement in SALT scores and a higher proportion achieved an absolute SALT score of ≤10 within 36 weeks compared to placebo, with minimal adverse effects reported. The FDA has approved Baricitinib for treating severe alopecia, but further research is needed to assess its long-term safety and confirm these findings in a larger cohort.